The product, called Nuvaxovid, is a protein-based vaccine. Health Canada said the vaccine was updated to target the JN.1 variant, an offshoot of Omicron. Nationally, the JN.1 group is ...
Dr Clive Dix said that Nuvaxovid has excellent clinical data and – as a it has good stability at fridge temperatures – could be easily rolled out with the flu vaccine next winter, and should ...
Results that may be inaccessible to you are currently showing.